JP2021502980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502980A5 JP2021502980A5 JP2020526482A JP2020526482A JP2021502980A5 JP 2021502980 A5 JP2021502980 A5 JP 2021502980A5 JP 2020526482 A JP2020526482 A JP 2020526482A JP 2020526482 A JP2020526482 A JP 2020526482A JP 2021502980 A5 JP2021502980 A5 JP 2021502980A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cancer
- antibody
- seq
- atpase activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586224P | 2017-11-15 | 2017-11-15 | |
| US62/586,224 | 2017-11-15 | ||
| US201862686149P | 2018-06-18 | 2018-06-18 | |
| US62/686,149 | 2018-06-18 | ||
| US201862733175P | 2018-09-19 | 2018-09-19 | |
| US62/733,175 | 2018-09-19 | ||
| PCT/EP2018/081364 WO2019096900A1 (en) | 2017-11-15 | 2018-11-15 | Potentiating the effect of atp release |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502980A JP2021502980A (ja) | 2021-02-04 |
| JP2021502980A5 true JP2021502980A5 (https=) | 2021-07-26 |
| JP7383609B2 JP7383609B2 (ja) | 2023-11-20 |
Family
ID=64332078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526482A Active JP7383609B2 (ja) | 2017-11-15 | 2018-11-15 | Ａｔｐ放出の効果の強力化 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190218304A1 (https=) |
| EP (1) | EP3710052A1 (https=) |
| JP (1) | JP7383609B2 (https=) |
| KR (1) | KR102781619B1 (https=) |
| CN (1) | CN111372606B (https=) |
| AU (1) | AU2018368541B2 (https=) |
| BR (1) | BR112020009655A8 (https=) |
| CA (1) | CA3075371A1 (https=) |
| IL (1) | IL273440A (https=) |
| SG (1) | SG11202002195YA (https=) |
| WO (1) | WO2019096900A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| EP3622092A4 (en) * | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| MY202018A (en) | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| BR112020006809A2 (pt) * | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| EP3788079A4 (en) | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| DK3807316T3 (da) | 2018-06-18 | 2024-07-29 | Innate Pharma | Sammensætninger og fremgangsmåder til behandling af cancer |
| MX2021012769A (es) | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| KR102856075B1 (ko) | 2020-07-17 | 2025-09-04 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그 동작 방법 |
| WO2022167999A1 (en) * | 2021-02-08 | 2022-08-11 | Takeda Pharmaceutical Company Limited | Combination therapy for cancer treatment |
| CN115975030B (zh) * | 2021-09-30 | 2023-09-26 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
| MX2024010646A (es) | 2022-03-03 | 2024-09-19 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos. |
| US20250188165A1 (en) * | 2022-03-04 | 2025-06-12 | Trishula Therapeutics Inc | Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| CA3005986A1 (en) * | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| EP3912681A1 (en) * | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| IL269150B2 (en) * | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| KR20230020023A (ko) * | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
-
2018
- 2018-11-15 KR KR1020207013452A patent/KR102781619B1/ko active Active
- 2018-11-15 WO PCT/EP2018/081364 patent/WO2019096900A1/en not_active Ceased
- 2018-11-15 CA CA3075371A patent/CA3075371A1/en active Pending
- 2018-11-15 SG SG11202002195YA patent/SG11202002195YA/en unknown
- 2018-11-15 EP EP18803967.1A patent/EP3710052A1/en active Pending
- 2018-11-15 CN CN201880070859.6A patent/CN111372606B/zh active Active
- 2018-11-15 AU AU2018368541A patent/AU2018368541B2/en active Active
- 2018-11-15 JP JP2020526482A patent/JP7383609B2/ja active Active
- 2018-11-15 BR BR112020009655A patent/BR112020009655A8/pt unknown
-
2019
- 2019-03-29 US US16/370,789 patent/US20190218304A1/en not_active Abandoned
-
2020
- 2020-03-19 IL IL273440A patent/IL273440A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502980A5 (https=) | ||
| JP7157181B2 (ja) | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 | |
| JP2020536109A5 (https=) | ||
| TWI686406B (zh) | 結合ｔｉｍ-３之抗體分子及其用途 | |
| ES2770684T3 (es) | Moléculas de anticuerpos contra LAG-3 y usos de los mismos | |
| Pogue et al. | Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| CN114245807A (zh) | Flt3l-fc融合蛋白和使用方法 | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2019527706A5 (https=) | ||
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2020513809A5 (https=) | ||
| TW201427664A (zh) | Ｔｅｃ家族激酶抑制劑佐劑療法 | |
| JP2019517549A5 (https=) | ||
| JP2009539380A5 (https=) | ||
| JP2016530323A5 (https=) | ||
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| IL274160B2 (en) | Methods and compositions for dosing allogeneic chimeric T cells for antigen receptors | |
| CN108883109A (zh) | 用于治疗急性髓性白血病的联合疗法 | |
| Tsukasaki et al. | Clinical trials and treatment of ATL | |
| US20220354851A1 (en) | Methods of treatment | |
| EP4568998A1 (en) | B7-h3 antigen-binding molecules | |
| AR074398A1 (es) | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa | |
| JP7715041B2 (ja) | 癌の治療及び／又は予防のための医薬品 |